Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- John Gerecitano, MD, PhD
Sana Biotechnology, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the University of Kansas Hospital
Kansas City, Kansas, United States
- Fred Hutchinson Cancer Center
Seattle, Washington, United States
- Swedish Cancer Institute
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Apr 2024
- Primary completion
- 31 Dec 2025
- Completion
- 31 Mar 2029
- Last update posted
- 28 Nov 2025
- Registered enrollment
- 6
- Registry id
- NCT06285422
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.